Copper peptides enlarge hair follicles in rodents and stimulate follicle cells in a dish, but every human hair study so far paired the peptide with something else. Here is what each study tested, what it found, and how it compares with minoxidil and finasteride.
Is GHK-Cu good for hair regrowth? The honest answer is that the copper peptide looks promising in the lab and has never been properly tested on its own in people with hair loss. Copper peptides, including GHK-Cu and its close relative AHK-Cu, enlarge hair follicles in rodents and stimulate human follicle cells in culture, yet every human hair study that included a copper peptide also included something else, whether that was a second active ingredient, a cocktail of growth factors, or minoxidil and dutasteride delivered together. None of those studies isolated what the copper peptide did by itself.
That gap matters to you if you are looking at copper peptide scalp serums, which are now often sold as a gentler alternative to minoxidil. This article walks through the studies one at a time, from the cell work to a scalp tattooing case series, and sets them next to the far larger evidence base behind the standard hair loss drugs. It is also worth knowing from the start that nearly all of the human hair data come from men, so if you are a woman with thinning hair, the evidence for your situation is thinner still. If you want the broader background first, our [GHK-Cu copper peptide overview](https://www.peptidepeppers.com/articles/ghk-cu-copper-peptide) covers the skin and wound healing research. This is educational content about published research, not medical advice, and GHK-Cu is not an approved hair loss treatment, so any decision about your hair is best made with a dermatologist.
Key takeaways
Tested alone in a human hair trial?
No. A 2026 systematic review called the human GHK-Cu literature "thin and fragmented," with most randomized trials being small facial cosmetic studies.
The famous human follicle study
Pyo and colleagues (2007) used AHK-Cu, a related copper tripeptide, on human follicles kept alive in a dish rather than GHK-Cu in people.
Only placebo controlled human trial
GHK combined with 5-aminolevulinic acid in 45 men for 6 months: hair count rose by 52.6 and 71.5 in the two treatment groups versus 9.6 on placebo.
Scalp tattooing case series
Minoxidil, dutasteride and 1.2% copper peptides in 7 men gave median top scalp regrowth of 26.5%, with no control arm.
Standard drugs for comparison
Minoxidil, finasteride and dutasteride have been compared across 23 studies in a 2022 JAMA Dermatology network meta analysis.
Sources: Najafi and colleagues, Archives of Internal Medicine Research, 2026; Pyo and colleagues, Archives of Pharmacal Research, 2007; Lee and colleagues, Annals of Dermatology, 2016; Kuceki and colleagues, JAAD International, 2025; Gupta and colleagues, JAMA Dermatology, 2022.
GHK-Cu is a three amino acid peptide made of glycine, histidine and lysine, bound to a copper ion. GHK occurs naturally in human plasma, and its copper binding strength is similar to the copper transport site on albumin, according to a 2008 review by Loren Pickart, the researcher who first isolated the peptide (doi.org/10.1163/156856208784909435).
The hair theory comes from what GHK-Cu does to skin cells in the lab. Pickart's review lists increased production of vascular endothelial growth factor (VEGF), more proliferation of fibroblasts and keratinocytes, new blood vessel growth, and an increase in "hair follicle size" among its reported actions. The dermal papilla, which is the cluster of cells at the base of each follicle that controls hair growth, is made of specialized fibroblasts, so a molecule that stimulates fibroblasts and blood supply is a reasonable candidate for follicle research.
A reasonable candidate is still a long way from a proven treatment. Most of these effects were measured in cell cultures or animals, and the review itself was written by an author with a long commercial interest in copper peptides.
The lab and animal studies consistently found that copper peptides enlarge follicles or stimulate follicle cells. They are the strongest part of the evidence, and they are also the part furthest from your scalp.
The earliest work was in rodents. Trachy, Fors, Pickart and Uno published hair follicle results for peptide copper complexes in C3H mice in 1991, and that work came out of ProCyte Corporation, a company developing copper peptides (doi.org/10.1111/j.1749-6632.1991.tb24420.x). In 1993, Uno and Kurata reported in the Journal of Investigative Dermatology that a copper binding peptide coded PC1031 enlarged follicles on the back skin of fuzzy rats, and that "the effect was similar to that of topical minoxidil" (doi.org/10.1111/1523-1747.ep12363275). Neither rodent paper establishes that the compound tested was GHK-Cu itself, since they describe peptide copper complexes and PC1031. That sentence, taken from a rat study, is the likely root of the claim you see online that copper peptides work as well as minoxidil.
The next step was human follicles in a dish. Pyo and colleagues at Seoul National University tested a tripeptide copper complex on human hair follicles kept alive outside the body and on cultured dermal papilla cells, publishing in Archives of Pharmacal Research in 2007 (doi.org/10.1007/BF02978833). At very low concentrations, the complex lengthened the follicles and increased dermal papilla cell proliferation. It also shifted markers of cell death in a protective direction, raising the Bcl-2/Bax ratio and lowering cleaved caspase 3, although the drop in the number of dying cells was not statistically significant.
There is a detail that almost every summary of the Pyo study leaves out, which is that the peptide tested was AHK-Cu (alanine, histidine, lysine) rather than GHK-Cu. The two are close relatives, but they are different molecules, and results for one cannot simply be assigned to the other.
The most recent animal work tackles delivery. A 2024 Bioactive Materials paper by Liu and colleagues addressed the practical problem that GHK-Cu does not cross skin easily (doi.org/10.1016/j.bioactmat.2023.10.002). The authors built an ionic liquid microemulsion that improved local delivery of the copper peptide in their tests, confirmed hair effects in mice, and found more activation of the Wnt/β-catenin pathway that regulates the hair cycle. The paper opens by calling copper peptides "a powerful hair growth promoter," but its own new evidence comes from mice.
Where the copper peptide hair evidence sits
| Evidence level | Studies | What they found | Peptide tested |
|---|---|---|---|
| Rodents | Trachy and colleagues, 1991; Uno and Kurata, 1993; Liu and colleagues, 2024 | Copper peptides enlarged follicles in mice and fuzzy rats; a new microemulsion improved delivery in mice. | Copper peptide complexes, PC1031, GHK-Cu |
| Human tissue in a dish | Pyo and colleagues, 2007 | Lengthened human follicles ex vivo and increased dermal papilla cell proliferation. | AHK-Cu (not GHK-Cu) |
| Humans, combination products | Lee 2016; Kapoor 2018; Kuceki 2025; Patel 2024 | Some improvement, but always alongside another active treatment. | GHK or copper tripeptide-1 plus other actives |
| Humans, copper peptide alone | None published | No controlled trial has tested GHK-Cu alone for hair loss. | None |
Sources: Trachy and colleagues, Annals of the New York Academy of Sciences, 1991; Uno and Kurata, Journal of Investigative Dermatology, 1993; Pyo and colleagues, Archives of Pharmacal Research, 2007; Liu and colleagues, Bioactive Materials, 2024; human studies as listed in the next table.
GHK-Cu has not been tested on its own for hair loss in humans. Four human studies involve a copper peptide and hair, and in every one of them the copper peptide was combined with at least one other active treatment, as the table below shows.
Human hair studies that included a copper peptide
| Study | Design | What was applied | People | Copper peptide alone? |
|---|---|---|---|---|
| Lee and colleagues, Annals of Dermatology, 2016 | Randomized, placebo controlled | 5-ALA plus GHK complex (ALAVAX), daily for 6 months | 45 men | No |
| Kapoor and Shome, J Cosmetic and Laser Therapy, 2018 | Open label, single arm | Injected growth factors, thymosin β4 and copper tripeptide-1 | 1000 patients | No |
| Kuceki and colleagues, JAAD International, 2025 | Retrospective case series, no control | Minoxidil 0.5%, dutasteride 0.1%, copper peptides 1.2% by scalp tattooing | 7 men | No |
| Patel and colleagues, Cureus, 2024 | Open label, 15 days, dandruff study | Hydroxy acid scrub plus serum with copper tripeptide-1 and other ingredients | Adults with dandruff | No |
Sources: Lee and colleagues, 2016; Kapoor and Shome, 2018; Kuceki and colleagues, 2025; Patel and colleagues, 2024. In the Lee trial, the abstract describes GHK without describing a copper complex.
Each of these studies is worth a closer look, because the headline numbers are easy to misread when you see them quoted on a product page.
The 5-ALA and GHK trial found more new hairs in both treatment groups than on placebo, but no improvement in hair length or thickness. Published by Lee and colleagues in Annals of Dermatology in 2016, it is the closest thing to a controlled human study of a GHK product for hair (doi.org/10.5021/ad.2016.28.4.438). Researchers at Kyungpook National University randomized 45 men with male pattern hair loss to a complex of 5-aminolevulinic acid and GHK called ALAVAX at 100 mg/ml, the same complex at 50 mg/ml, or placebo, applied once a day for 6 months.
Hair count rose by 52.6 in the higher dose group and 71.5 in the lower dose group, compared with 9.6 on placebo. The authors found no statistically significant difference in hair length or hair thickness between the three groups at 6 months, and they reported no adverse events. Satisfaction rated good or better was 26.7% in the higher dose group, 14.3% in the lower dose group and 7.1% on placebo.
Increase in hair count over 6 months, 5-ALA plus GHK trial (45 men)
The product combined GHK with 5-aminolevulinic acid, so the result cannot be attributed to GHK alone. Hair length and thickness did not differ significantly between groups. Source: Lee and colleagues, Annals of Dermatology, 2016.
Two points limit what this trial can tell you about GHK-Cu. The active product paired GHK with 5-aminolevulinic acid, so the trial cannot say which ingredient drove the result, and the abstract describes the peptide as GHK without describing a copper complex. On top of that, the trial was small, the lower dose did better than the higher one, and the result has not been replicated.
"Every human hair study that included a copper peptide also included something else, so none of them can tell you what the copper peptide did on its own."
Patients rating satisfaction as good or better (%)
Source: Lee and colleagues, Annals of Dermatology, 2016.
The 1000 patient injection study sounds large, but its design makes it weak evidence for any single ingredient. Kapoor and Shome described it in the Journal of Cosmetic and Laser Therapy in 2018 as an open label, single arm pilot, which means that everyone received the treatment and everyone knew it (doi.org/10.1080/14764172.2018.1439965). The injected formula contained VEGF, basic fibroblast growth factor, insulin like growth factor, keratinocyte growth factor, thymosin β4 and copper tripeptide-1, and it was given every 3 weeks for 8 sessions.
The authors reported reduced hair fall on a pull test in 83% of patients, and 75% of patients believed the injections were helping. With six active ingredients and no comparison group, there is no way to attribute any of that result to the copper peptide.
The scalp tattooing case series showed meaningful regrowth in a handful of men, but it delivered three drugs at once and had no control group. Kuceki and colleagues, writing in JAAD International in 2025, reviewed 7 men aged 28 to 55, with a median age of 42, who had an unsatisfactory response to at least a year of standard treatment (doi.org/10.1016/j.jdin.2025.01.012). The men received 5 monthly sessions of a solution containing minoxidil 0.5%, dutasteride 0.1% and copper peptides 1.2%, pushed into the scalp with a tattoo machine.
Blinded dermatologists rated the photos. The median top scalp Severity of Alopecia Tool score fell from 40.0% to 7.5%, and 5 of the 7 men (71.4%) reached more than 10% top scalp regrowth. Median regrowth was 26.5%, compared with 10% in an earlier protocol from the same field that used 3 sessions of minoxidil and dutasteride without copper peptides.
Scalp tattooing with minoxidil, dutasteride and copper peptides (7 men)
Median top scalp SALT score (%)
Median top scalp regrowth (%)
A lower SALT score means less visible scalp. The two protocols also differed in number of sessions and needle depth (2 mm versus 1.5 mm), and there was no control arm. Source: Kuceki and colleagues, JAAD International, 2025.
That comparison is the only hint anywhere in the human literature that adding a copper peptide might add something, and it is a very thin hint. The authors themselves list three differences between the protocols, namely more sessions, the copper peptides, and deeper needle penetration (2 mm instead of 1.5 mm). They also note the absence of a control arm and of objective hair density measurements, so the extra regrowth cannot be credited to any one of those changes.
The copper peptide dandruff study does not count as hair regrowth evidence. Patel and colleagues, writing in Cureus in 2024, tested a 15 day scalp regimen for dandruff that combined a hydroxy acid scrub with a serum containing copper tripeptide-1, witch hazel, hesperidin, hyaluronic acid and pea protein (doi.org/10.7759/cureus.70108). They reported increases of 12.48% in hair density and 25.36% in hair thickness on a scalp imaging device. However, the study was open label, lasted two weeks, was run in people with dandruff rather than hair loss, and the authors disclosed links to the product's manufacturer.
There is no head to head human trial of GHK-Cu against minoxidil, finasteride or dutasteride, so a direct comparison is not possible. What you can compare is the depth of evidence behind each option.
A 2022 network meta analysis in JAMA Dermatology by Gupta and colleagues screened 848 records and pooled 23 eligible studies of minoxidil, finasteride and dutasteride in men with androgenetic alopecia (doi.org/10.1001/jamadermatol.2021.5743). Because the evidence base was large enough, the authors could rank doses against each other. At 24 weeks, dutasteride 0.5 mg/d produced the largest gain in total hair count, beating finasteride 1 mg/d by 7.1 hairs/cm² and 2% topical minoxidil by 8.5 hairs/cm², while oral minoxidil 5 mg/d produced the greatest increase in terminal hairs at 24 weeks.
Evidence depth: standard hair loss drugs versus GHK-Cu
| Evidence feature | Minoxidil, finasteride, dutasteride | GHK-Cu |
|---|---|---|
| Studies pooled in a network meta analysis | 23 (Gupta and colleagues, 2022) | None |
| Placebo controlled trials of the compound alone | Yes | None found |
| Hair count measured in hairs/cm² at 24 and 48 weeks | Yes | No |
| Best gain in total hair count at 24 weeks | Dutasteride 0.5 mg/d, ahead of finasteride 1 mg/d by 7.1 hairs/cm² | Not measured |
| Human evidence base | Multiple randomized trials | One combination trial and uncontrolled combination studies |
Sources: Gupta and colleagues, JAMA Dermatology, 2022; Najafi and colleagues, Archives of Internal Medicine Research, 2026.
The idea that a copper peptide is as good as minoxidil traces back to a rat study rather than to any human comparison. If you are weighing a copper peptide serum against an established treatment, that history is worth keeping in mind.
"The claim that copper peptides match minoxidil comes from fuzzy rats in 1993, and no human trial has ever tested it."
The human GHK-Cu hair evidence is thin for two recurring reasons, which are the difficulty of getting the peptide into skin and the narrow circle of researchers who have studied it.
Delivery comes first. GHK-Cu is water loving and charged, and the Liu 2024 paper states that "challenges in delivering GHK-Cu topically" limit its use, which is why research groups are testing microemulsions, microneedles and tattooing. A serum that sits on the surface of your scalp may never reach the dermal papilla in meaningful amounts. Our article on [GHK-Cu injection dosage and frequency](https://www.peptidepeppers.com/articles/ghk-cu-peptide-injection-dosage-and-frequency) explains why the route matters so much for this peptide.
Research independence is the second problem. A 2026 systematic review by Najafi and colleagues in Archives of Internal Medicine Research screened 1,247 records and kept 64 (doi.org/10.26502/aimr.0255). The reviewers found that about 35% of the GHK-Cu primary literature in their window included Pickart or Anna Margolina of Skin Biology as an author, and they wrote that this concentration "limits the independence of the evidence base." The same review described the human GHK-Cu literature as "thin and fragmented" and listed androgenetic alopecia among the conditions where well designed human trials are still needed.
There is no published evidence that GHK-Cu treats telogen effluvium, the diffuse shedding that follows stress, illness, rapid weight loss or childbirth. Telogen effluvium usually settles once the trigger passes, which makes it especially easy to credit a product for a recovery that was going to happen anyway. If your shedding started after a big change, such as beginning a GLP-1 medication, our guide to [GLP-1 hair loss and telogen effluvium](https://www.peptidepeppers.com/articles/glp-1-hair-loss-telogen-effluvium) explains the usual timeline.
A useful GHK-Cu hair study would test the peptide alone against a matched vehicle, in people with a clearly defined type of hair loss, for at least 24 weeks, with hair counts measured in hairs/cm² by phototrichogram. It would ideally include a minoxidil arm, enroll women as well as men, be run by investigators without a commercial stake, and report the actual concentration and delivery method used. None of the published studies meets all of those criteria.
GHK-Cu has a believable biological story for hair and a consistent set of positive results in cell cultures and rodents. What it does not have is a single human trial that tested the copper peptide alone against a placebo for hair loss, and the most quoted human follicle study actually used a related peptide, AHK-Cu. The human studies that do exist mixed copper peptides with 5-aminolevulinic acid, growth factors, minoxidil or dutasteride, so their results cannot be credited to the peptide.
If you enjoy a copper peptide scalp serum, there is little evidence of harm in the small studies so far, but you should not expect it to replace a treatment with a real trial record. If your hair loss is progressing, a dermatologist can confirm the cause and talk you through options such as minoxidil and finasteride, which have a far deeper trial record behind them.
Pyo HK, et al. The effect of tripeptide copper complex on human hair growth in vitro. Archives of Pharmacal Research, 2007. doi.org/10.1007/BF02978833
Trachy RE, Fors TD, Pickart L, Uno H. The hair follicle stimulating properties of peptide copper complexes. Results in C3H mice. Annals of the New York Academy of Sciences, 1991. doi.org/10.1111/j.1749-6632.1991.tb24420.x
Uno H, Kurata S. Chemical agents and peptides affect hair growth. Journal of Investigative Dermatology, 1993. doi.org/10.1111/1523-1747.ep12363275
Lee WJ, et al. Efficacy of a complex of 5-aminolevulinic acid and glycyl histidyl lysine peptide on hair growth. Annals of Dermatology, 2016. doi.org/10.5021/ad.2016.28.4.438
Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth. Journal of Cosmetic and Laser Therapy, 2018. doi.org/10.1080/14764172.2018.1439965
Kuceki G, et al. Enhanced hair regrowth with five monthly sessions of minoxidil, dutasteride and copper peptides tattooing for androgenetic alopecia. JAAD International, 2025. doi.org/10.1016/j.jdin.2025.01.012
Liu T, et al. Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application. Bioactive Materials, 2024. doi.org/10.1016/j.bioactmat.2023.10.002
Pickart L. The human tripeptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition, 2008. doi.org/10.1163/156856208784909435
Najafi N, et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery. Archives of Internal Medicine Research, 2026. doi.org/10.26502/aimr.0255
Gupta AK, et al. Relative efficacy of minoxidil and the 5α reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta analysis. JAMA Dermatology, 2022. doi.org/10.1001/jamadermatol.2021.5743
Patel MN, et al. An assessment of the safety, efficacy, and tolerability of a novel scalp treatment regimen combining a hydroxy acid based scrub and copper tripeptide serum. Cureus, 2024. doi.org/10.7759/cureus.70108
GHK-Cu has promising lab and animal evidence for hair growth, but it has not been tested alone in a controlled human hair loss trial. Rodent studies showed follicle enlargement, and a related copper peptide, AHK-Cu, lengthened human follicles in culture. Every human study so far combined a copper peptide with other active treatments, so its own effect on scalp hair is unknown.
No human trial has compared GHK-Cu with minoxidil. The comparison comes from a 1993 rat study in which a copper binding peptide enlarged follicles with an effect "similar to that of topical minoxidil." Minoxidil, by contrast, has been compared with finasteride and dutasteride across 23 studies in a 2022 JAMA Dermatology network meta analysis.
The Pyo 2007 study showed that a copper peptide lengthened human hair follicles kept alive in a dish and stimulated dermal papilla cells, but it did not involve living people. It also tested AHK-Cu, a related tripeptide, rather than GHK-Cu, which is an important difference that many product pages leave out.
A 2016 Annals of Dermatology trial gave 45 men with male pattern hair loss a combination of 5-aminolevulinic acid and GHK, or placebo, for 6 months. Hair count rose by 52.6 and 71.5 in the two treatment groups versus 9.6 on placebo, with no difference in hair length or thickness. Because GHK was paired with another compound, the trial cannot show what GHK did alone.
Delivery is a known weakness of copper peptides. A 2024 Bioactive Materials paper stated that challenges in delivering GHK-Cu topically limit its use, and researchers have turned to microemulsions, microneedles and tattooing to push more peptide into the skin. Whether a typical over the counter serum delivers enough peptide to the follicle has not been measured in human studies.
The small human studies that included copper peptides reported few problems, since the 2016 GHK trial reported no adverse events and the 2025 tattooing series observed no scarring or infection. These studies were small and short, so they cannot rule out uncommon reactions. If you have a sensitive scalp or a skin condition, check with a dermatologist before starting a new topical.
The only published data on that combination come from a 2025 case series of 7 men who received minoxidil, dutasteride and 1.2% copper peptides together by scalp tattooing. Median top scalp regrowth was 26.5%, but there was no control group and three drugs were given at once. Whether adding a copper peptide to minoxidil improves results has not been tested in a controlled trial.
GHK was first isolated by Loren Pickart, and a 2026 systematic review found that about 35% of the GHK-Cu primary literature in its window included Pickart or Anna Margolina of Skin Biology as an author. The reviewers called the work scientifically substantive but said the concentration of authorship limits the independence of the evidence, so independent and adequately powered hair trials are still needed.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before beginning any peptide protocol.
About this post
Related reading